Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01155817 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT01155817: Completed Phase 1 study, sponsored by Stanford University.
NCT01155817 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01155817, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
PRIMARY OBJECTIVES: Determine the safety and tolerability of nilotinib in steroid dependent / refractory cGVHD. SECONDARY OBJECTIVES: Determine the clinical efficacy of nilotinib in steroid dependent / refractory cGVHD.
Interventions
- DRUG Nilotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2010-08 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01155817
The ClinicalTrials.gov registry entry for NCT01155817 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nilotinib is the first listed.
NCT01155817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01155817 about?
NCT01155817 is a clinical study titled "Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease". PRIMARY OBJECTIVES: Determine the safety and tolerability of nilotinib in steroid dependent / refractory cGVHD. SECONDARY OBJECTIVES: Determine the clinical efficacy of nilotinib in steroid dependent / refractory cGVHD.
What is the current status of trial NCT01155817?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2010-08. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01155817?
The interventions under investigation include: Nilotinib (DRUG).
Who is sponsoring clinical trial NCT01155817?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.